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Abstract
Background: Elephant Endotheliotropic Herpesviruses (EEHVs) can cause acute haemorrhagic disease in young
Asian elephants (Elephas maximus) and clinical EEHV infections account for the majority of their fatalities. The anti-
herpesviral drug famciclovir (FCV) has been used routinely to treat viraemic at-risk elephants, but thus far without
proven efficacy. This paper presents clinical and virological investigations of two EEHV-1A infected elephants treated
with FCV, and discusses anti-herpesvirus therapies of viraemic elephants.
Cases presentations: Two 1.5 year old male Asian elephants at a zoological collection in the UK developed clinical
EEHV-1A infections. Case 1 showed signs of myalgia for the duration of 24 hours before returning back to normal.
EEHV-1A DNAemia was confirmed on the day of clinical signs and continued to be present for 18 days in total.
Trunk shedding of the virus commenced 10 days after detection of initial DNAemia. Case 2 tested positive for
EEHV-1A DNAemia in a routine blood screening sample in the absence of clinical signs. The blood viral load
increased exponentially leading up to fatal clinical disease seven days after initial detection of DNAemia. Both calves
were treated with 15 mg/kg FCV per rectum on detection of DNAemia and penciclovir, the FCV metabolite, could
be detected in the blood at assumed therapeutic levels. The early indicators for clinical disease were a marked
absolute and relative drop in white blood cells, particularly monocytes prior to the detection of viraemia. The most
prognostic haematological parameter at later stages of the disease was the platelet count showing a continuous
sharp decline throughout, followed by a dramatic drop at the time of death.
Conclusions: The EEHV-1A viraemic animals investigated here further highlight the ongoing threat posed by these
viruses to juvenile Asian elephants. The findings call into question the efficacy of rectal FCV in clinical cases and
direct towards the use of alternative anti-herpesvirus drugs and complementary treatments such as plasma
infusions if no improvement in either viral load or the above-mentioned blood parameters are observed in the
initial days of viraemia despite anti-herpesvirus therapy.
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Background
Elephant Endotheliotropic Herpesviruses (EEHVs) or
Elephantid Herpesviruses (ElHVs) belong to the genus
Proboscivirus of the family Herpesviridae [1, 2] and fall
into 7 genotypes [3–9]. Phylogenetically, the viruses are
most closely, although distantly, related to human cyto-
megalovirus (HCMV) and three human Roseolo viruses
(human herpesvirus-6A, -6B, and -7), all members of the
subfamily Betaherpesvirinae [1].
EEHVs, in particular EEHV-1, are the cause of acute
haemorrhagic disease (EEHV-HD) in young Asian ele-
phants (Elephas maximus), and clinical EEHV infec-
tions account for most of the fatalities in juvenile Asian
elephants, both in their natural habitat and in captivity
[7–13]. EEHV-1 induced acute haemorrhagic disease is
manifested initially by sudden onset of non-specific
clinical signs, which often develop into haemorrhagic
disease and sudden death within 1 to 7 days [9, 12]. It
has also been documented that EEHV viraemia is de-
tectable at least several days before the onset of clinical
signs [13, 14]. To enable early therapeutic intervention
in response to detection of EEHV viraemia, some zoo-
logical collections have implemented regular blood
sampling and laboratory testing of juvenile Asian
elephants.
Conferring from herpesviruses’ properties, it could be
assumed that once an elephant is infected it remains a
latent carrier for life. Screenings of elephant herds have
revealed widespread prevalence of the viruses and their
periodical reactivation and shedding through biological
fluids, especially trunk secretions [13–19]. Routes of
EEHVs transmission to naïve individuals are still unclear,
however, considering other herpesviruses’ transmission
routes, contact with infected bodily secretions is a very
likely possibility and vertical transmission cannot be
excluded.
EEHVs, similar to viruses in the subfamily Alphaherpes-
virinae and Gammaherpesvirinae, comprise of a genome
with a thymidine kinase (TK) and a serine/threonine pro-
tein kinase (PK) [7, 20], which encode enzymes crucial for
processing many anti-herpesviral prodrugs into their active
derivatives. Based on approaches in treatment of other her-
pesviruses with TK and PK genes, three nucleoside ana-
logues [famciclovir (FCV) and more recently ganciclovir
(GCV) and aciclovir (ACV)] have been administered to
treat viraemic elephant calves, with the aim to avert pro-
gression to clinical disease, but as yet without proven clin-
ical efficacy. It is known that several elephant calves have
survived laboratory confirmed EEHV infections. These ele-
phant calves were treated with FCV at doses of 5.5-8.0 mg/
kg twice daily (BID) rectally [9, 18, 19, 21–24] or with
GCV at 5 mg/kg BID intravenously followed by oral
administration [14, 25]. One elephant calf with advanced
EEHV-1 clinical signs has been treated successfully with
ACV at 12mg/kg BID intravenously for 15 days along with
penicillin G and supportive treatment including vitamin C,
physiological saline and 5 % Dextrose [26]. Apart from the
latter case, it seems likely that many of surviving elephant
calves represent relatively mild cases, in view of length of
time taken to reach the highest viral load, level of viraemia
at this point and recovery of blood parameters. It is there-
fore likely that these affected individuals might have recov-
ered without drug intervention [9].
FCV, chemically known as 2-[2-(2-amino-9H-purin-9-
yl)ethyl]-1,3-propanediol diacetate, is a synthetic acyclic
guanosine analogue that is rapidly de-acetylated and
oxidized in the body to its metabolite penciclovir (PCV).
Activation of PCV requires phosphorylation in the
virally infected cells by viral and cellular kinases. The
drug has a half-life of approximately three hours and its
catabolite is excreted renally [27]. PCV interacts with
herpesvirus DNA polymerase, the enzyme responsible
for creating DNA molecules through assembly of nucle-
otides (building blocks of DNA), and thus terminates
DNA synthesis. A recent study showed that when
administered to healthy young Asian elephants both
orally or per rectum, FCV is absorbed and metabolised
to PCV with plasma levels considered therapeutic in
humans [27, 28]. ACV, another guanosine analogue with
a biological half-life of 2-4 hours, is still used widely for
the treatment and prevention of clinical Herpes Simplex
Virus (HSV) and Varicella Zoster Virus (VZV) diseases
in humans. Activation of ACV within cells via the viral
and cellular kinases yields ACV–triphosphate, which
interacts adversely with herpesvirus DNA synthesis [29].
GCV is another guanosine analogue that is activated via
viral and cellular kinases. Its oral prodrug valganciclovir
(VGCV) is the most commonly prescribed drug for the
prevention and therapy of HCMV in immunocomprom-
ised patients [29].
This paper describes the investigations into two
EEHV-1A viraemic elephants from a UK zoological
collection that were both treated with FCV. It also dis-
cusses findings of the investigations in relation to anti-
herpes viral therapies in EEHV viraemic elephants.
Case presentations
Virus screening
Blood samples of EDTA whole blood and blood swabs
were collected under trained behaviour from an ear vein
after aseptic preparation of the medial aspect of the ear
pinna. For EDTA whole blood samples, the animal was
placed in lateral recumbency and the lowermost ear was
sampled, using a standard 21G 1-inch needle and a
Vacutainer® blood collection system. For blood swabs, a
dry 6-inch foam tipped swab (Sigma Aldrich, UK) was
used for collection of a drop of blood after puncture of
an ear vein with an insulin needle, with the elephant in
Dastjerdi et al. BMC Veterinary Research  (2016) 12:178 Page 2 of 11
standing position. Blood samples were kept at room
temperature before being shipped to the laboratory,
where they were stored at 4–8 °C until being processed.
Under trained behaviour, conjunctival swabs and trunk
swabs were collected. Conjunctival swabs were collected
using a sterile dry swab for each eye, running these on
the inside of the lower palpebra. Trunk secretions from
the mucosa of each naris were collected on a dry 6-inch
foam tipped swab at a depth of approximately 8–10 cm,
under trained behaviour, and stored at −20 °C prior to
further testing. Blood smears were made of freshly col-
lected EDTA blood samples, air dried and stained with
Diff-Quick (LabPak, UK) for an in-house relative white
blood cell (WBC) differential count.
Nucleic acid was extracted from 140 μl EDTA whole
blood using the QIAamp® Viral RNA Mini kit (Qiagen,
UK) according to the manufacturer’s protocol. For blood
swabs, 560 μl buffer AVL from the kit were directly added
to the foam tipped swabs, left for 15 minutes at room
temperature, vortexed and spun briefly, and processed as
per the manufacturer’s instructions. To process trunk
swab samples for nucleic acid extraction, 300 μl PBS and
6–8 glass beads (3 mm in diameter) were added to the
swab inside a 2 ml Eppendorf tube, vortexed briefly and
incubated for 30 minutes at room temperature. The tube
content was then vortexed and nucleic acid was extracted
following the EDTA whole blood protocol using 140 μl of
the cleared suspension.
The qPCR used in this study was performed as described
[16] using the QuantiFast® Pathogen PCR + IC kit (Qiagen).
Briefly, 2 μl extracted DNA was added to 0.1 μl each for-
ward and reverse primer (100 pmol/μl), 0.05 μl hydrolysis
probe (100 pmol/μl), 5 μl 5× QuantiFast Pathogen Master
Mix, 0.5 μl 50× High-ROX Dye solution, and 17.25 μl
RNase-Free Water. The qPCR was performed on a
MX3005P machine (Agilent Technologies, UK) using the
cycling conditions of one cycle of 95 °C for five minutes
followed by 45 cycles of 95 °C for 15 seconds, 60 °C for 30
seconds, and signal acquisition at the end of each cycle.
The conventional PCRs were carried out as described [30]
using several primer pairs to amplify partial sequences of
polymerase (POL), glycoprotein L (gL) and gM genes.
The DNA standard used was a HPLC purified 100 bases
synthetic oligonucleotide (Eurofins Genomics, UK),
identical to the sequence of the qPCR target, diluted to
provide serial copy numbers from 106 to 101 copies per
PCR test. The synthetic oligonucleotide dilutions were run
in triplicate in the PCRs to create a standard curve for
EEHV genome quantification.
Supportive therapy and drug administration
Rectal fluids were provided after manual removal of all
faeces from the rectum. Several litres of hand-warm
water were then deposited into the distal colon at
approximately one meter depth, through a standard gar-
den hose pipe. Intravenous (i/v) access was acquired
after antiseptic preparation of the medial aspect of the
ear pinna, using an 18G 2.5-inch indwelling catheter
(Milacath®, Mila International, USA) in an ear vein. The
catheter was secured using Durapore® tape and super-
glue. Standard giving sets were used for i/v fluids and
filtered giving sets for the administration of blood and
blood components (Baxter, UK). Plasma was collected
from adult herdmates under trained behaviour, in lateral
recumbency from either an ear vein or a medial hind leg
vein, in one litre citrate blood collection bags (Crusse,
Denmark), stored for a minimum of eight hours at 5 °C
and separated using manual pressure. The plasma was
then stored at 5 °C and warmed to room temperature
prior to administration.
Anti-herpes viral treatment consisted of either FCV or
GCV. FCV (Novartis Pharmaceuticals, UK) 250 and/or
500 mg tablets were crushed using a pestle and mortar
and suspended in hand warm water. Using a 60 ml
syringe and a meter long tube, the suspension was ad-
ministered in the distal colon after removal of all faeces
as described above. GCV (Cymevene® 500 mg, Roche,
UK) was diluted in one litre of physiological saline
attached to a giving set and an i/v catheter, and adminis-
tered slowly over a period of one hour.
For measurement of plasma levels of GCV and PCV, the
FCV metabolite, whole blood samples obtained approxi-
mately 6-10 hours following drugs administration, were
centrifuged at 800 × g for 10 minutes and plasma was col-
lected and stored at −20 °C for later analysis. Plasma sam-
ples were analysed at the College of Veterinary Medicine,
University of Tennessee, USA using a reverse phase HPLC
method with solid phase extraction (SPE). The compounds
were separated on an Atlantis T3 (4.6 × 250 mm) column
with a mobile phase of 10 mM ammonium phosphate pH
2.9 and acetonitrile (95:5). The flow rate was 1.2 ml/min
and fluorescence was measured at excitation 253 nm and
emission 360 nm. Standard curves for plasma analysis were
prepared by fortifying untreated, pooled elephant plasma
with the drug to produce a linear concentration range of
10-5000 ng/ml. Average recovery was 100 % while intra
and inter-assay variability ranged from 0.5 to 5.1 %. The
lower limit of quantification was 10 ng/ml.
Case 1
In 2013, 1.5 year old male Asian elephant calf ‘Scott’
was presented with unwillingness to bend either fore-
leg, swinging both legs forward when walking. Its ears
were drooping, the head was down and the calf was off
solid food. An EDTA whole blood sample taken on the
day tested qPCR positive for EEHV-1 DNA. Prior to
this event, routine blood samples and trunk swabs
tested negative for EEHV-1. Using a qPCR assay, the
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blood viral load was determined as 8.16*103 viral gen-
ome copies (vgc)/ml (Fig. 1). Genomic analysis of this
EEHV-1 by sequencing of PCR amplicons of partial
viral POL, gL and gM genes identified the virus as
EEHV-1A genotype. The sequences comparison with
those of two EEHV-1A fatalities in 2009 (Riddle and
Betts) at the collection revealed several nucleotide
substitutions in the POL, gL and gM gene segments, in-
dicating a genomically different virus from those in
Riddle and Betts (Fig. 2).
Treatment with 15 mg/kg FCV three times daily
(TID) per rectum was instigated eight hours after
these initial clinical signs. The first two treatments,
six hours apart, consisted of ground FCV tablets sus-
pended in ultrasound gel (Healthlife®, Barclays-Swan
Ltd, UK); however, most of the drug was expelled at
the next defaecation. Twelve hours after the initial
presentation, the calf started to voluntarily bend his
right foreleg again, and by the next morning, despite
some stiffness in the shoulders, the legs were in nor-
mal use and its appetite had returned. The dose of
FCV was therefore reduced to 12 mg/kg TID (Day 1);
this time dissolved in hand warm water and placed
1.5 meters deep into the rectum. All clinical signs
were resolved by Day 2, when the blood viral load
peaked at 3.61*104 vgc/ml, after which it started to
decrease gradually. The FCV dose was further re-
duced to 8 mg/kg BID on Day 7. Full haematology at
this point showed a relatively low monocyte count
(5.94*109/L, 26 % of WBC), but was normal (51 % of
WBC) when tested three weeks later (Table 1a). No
virus was detectable in the blood from Day 18 on-
wards (Fig. 1), and FCV treatment ceased on Day 21.
Viral DNA excretion through eye (data not shown)
and trunk secretions commenced on Day 10 and con-
tinued for at least two months, with a peak at around
Day 48 of 4.66*103 vgc/test reaction. No further sam-
ples were tested beyond Day 57.
As a pre-emptive measure, the calf ’s two siblings, a 3-
year old male and a 4-year old female, were treated sim-
ultaneously with 12 mg/kg FCV TID from Day 0 to Day
6, which was tapered to 8 mg/kg BID from Day 7 to Day
12, after which treatment ceased. Neither sibling was
positive for EEHV-1 DNA in blood or bodily secretions
throughout this period.
Plasma PCV levels, measured at trough levels 8-10
hours following the latest FCV administrations in both
Case 1 (Fig. 3) and its male sibling (data not shown),
ranged between 68 and 934 ng/ml. Levels measured at
the dosing regimens of 15 mg/kg TID and 12 mg/kg
TID reached values considered therapeutic in humans
with genital herpes (>100 ng/ml) [27].
Case 2
In 2015, a blood swab collected during routine weekly
sampling of 1.5 year old male calf ‘Max’ tested positive
for EEHV-1 DNA by qPCR. This result was confirmed
by a subsequent EDTA whole blood sample that tested
qPCR positive at 5.0*102 vgc/ml of blood. At this point
monocytes were abundant (12.46*109/L, 54 % of WBC)
and the platelet count was 950*109/L. (Table 1b, Day
-33). A follow-up blood sample four days later was
EEHV-1 DNA negative by qPCR and the calf remained
negative on four subsequent blood swabs taken during a
three-week period. On week 4 and one day prior to the
calf being diagnosed again with EEHV-1 DNAemia the
calf was presented with a swollen right temporal gland,
which was painful on palpation and from which purulent
discharge could be expressed. The gland was treated
with pevidine (Sanofi, UK) flushes and topical amoxicil-
lin/clavulanic acid application following bacteriological
culture and sensitivity testing. After this positive EEHV
Fig. 1 EEHV-1A DNA levels in blood and trunk secretions of Case 1. Clinical suspicion of EEHV infection was confirmed by detection of EEHV-1A
DNA in blood. The animal showed clinical signs suggestive of active EEHV-1A infection on Day 0 and Day 1. EEHV-1A DNA load in EDTA whole
blood (solid line) and trunk secretions (dashed line) was measured using a qPCR
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Fig. 2 Nucleotide sequence comparison of the EEHV-1A detected. Partial nucleotide sequences of DNA polymerase [U38/POL (194 bp)], glycoprotein
L [U82/gL (381 bp)] and glycoprotein M [U72/gM (500 bp)] from Case 1 and Case 2 were compared with those of two previous EEHV-1A fatalities
(Riddle and Betts) from the same zoological collection. Sequences were aligned using the MegAlign 13 software of the DNASTAR Lasergene 13
package (DNASTAR Inc. Madison, USA). Identical nucleotides to those of Case 1 are denoted by dots in the alignments
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qPCR result from a blood swab, an EDTA whole blood
sample also tested positive, with a viral load of 1.2*105
vgc/ml, the monocyte count had markedly reduced to
0.8*109/L (13 % of WBC) and the platelet count almost
halved to 560*109 /L, in the absence of clinical signs
(Day -5). PCR results for this sample became available
two days after the actual sampling date and treatment
was immediately instigated at 15 mg/kg FCV TID per
rectum. Blood samples were then taken regularly for
EEHV-1 qPCR, viral quantification and haematology.
Table 1 Haematological parameters of Case 1 and Case 2 measured during clinical EEHV-1A infection
A
Days WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
7 22.85 7.77 8.91 5.94 (26 %) 0.23 0
23 13.69 5.75 2.87 6.16 (45 %) 0 0
213 15.91 4.61 5.73 5.25 (33 %) 0.32 0
Physiological mean
(% of WBC)
15.51 3.77 (25.5 %) 5.02
(23.65 %)
6.46
(50 %)
0.24
(1.55 %)
0.02
(0.10 %)
Days RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH
(pg)
MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
7 3.54 13.4 37.7 107 37.8 35.5 14.3 470 36
23 5.06 19.2 55.1 109 37.9 34.8 14.5 968 55
213 3.62 13.3 39.2 108 36.8 33.9 13.9 996 37
Physiological
(mean)
3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
B
Days EEHV-1A
(vgc/ml)
WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
-33 5.0 × 102 23.08 4.62 5.77 12.46 (54 %) 0 0
-29 ND 25.34 4.56 7.6 13.18 (52) % 0 0
-5 1.2 × 105 6.18 3.46 1.85 0.8 (13 %) 0.06 0
-3 2.7 × 106 7.35 5.22 1.32 0.81 (11 %) 0 0
0 7.2 × 106 13.25 8.22 2.65 2.25 (17 %) 0.13 0
1 1.9 × 107 12.925 7.565 2 2.975 (23 %) 0 0.195
Physiological mean
(% of WBC)
15.51 3.77 (25.5 %) 5.02 (23.65 %) 6.46 (50 %) 0.24 (1.55 %) 0.02 (0.10 %)
Days RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH
(pg)
MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
-33 3.65 14.6 43.2 118.3 39.9 33.7 13.9 950 42
-29 3.58 14.5 41.4 115.5 40.4 35 38.1 760 38
-5 3.48 14.2 41.8 120.4 41 34 14 560 37
-3 3.36 14.2 38.4 114.4 42.4 37.1 13.7 183 38
0 2.89 12.4 32.9 113.7 42.9 37.8 13.8 98 34
1 3.07 12.95 35.05 114.2 42.2 36.9 13.6 13 36.5
Physiological mean 3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
The haematological parameters for Case 1 (A) were only available for Days 7, 23 and 213 following suspicion of clinical EEHV-1A infection. The haematological
parameters and viral load for Case 2 (B) were measured on several occasions from 33 days prior to the observation of signs indicative of clinical EEHV-1A infection
(Day 0) to the Day 1 when the elephant succumbed to the infection at midnight. Normal platelet range of live juveniles in the collection was established, during a
period of seven months from 20 blood samples of the elephants, to be at 372-878*10e9/L (mean of 625*10e9/L). The rest of the physiological parameters were
from 24 measurements from four individuals under eight years of age (age range at time of sampling: 1.5-7y). Parameter values with a substantial change are
highlighted in bold. Percentages of monocytes in the white blood cells are also given in the table
vgc/ml, viral genome copies per millilitre of EDTA whole blood; WBC, white blood cell count; RBC, red blood cell count; HGB, haemoglobin; HCT, haematocrit;
MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHV, mean corpuscular haemoglobin volume; RDW, red blood cell distribution width; PLT,
platelet count; PCV, packed cell volume; ND, not detected
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Genomic analysis of this EEHV-1 by sequencing of
PCR amplicons of partial viral POL, gL and gM genes
identified the virus as EEHV-1A genotype. However,
comparing these nucleotide sequences to those of Case
1, it was revealed that the virus was genomically slightly
different, but both cases were more dissimilar to Riddle
and Betts (Fig. 2). Nucleotide sequences of the partial
segments of the three genes for Riddle and Betts were
identical. This was not unexpected as the two fatalities
occurred within two weeks of each other, but longer se-
quence reads would be necessary to verify this further.
Viral load increased exponentially as time progressed,
during which the monocyte count stabilised around
2.54*109/L (17 % of WBC), but platelet counts showed a
continuous decline (Table 1b). Lymphocyte count has
also shown substantial reduction on the detection of
DNAemia, but other haematological parameters such as
neutrophil and basophil counts remained unchanged.
PCV plasma levels as high as 934 ng/ml were attained
during the first days of treatment (Fig. 3). Five days into
the DNAemia, the calf started to show signs of lethargy.
At this point, PCV plasma levels had dropped to 303
ng/ml, about a third of its previous peak.
The decision was made to start i/v fluids, consisting of
Harmann’s (15 ml/kg/h, Vetivex 11, Dechra, UK) supple-
mented with Duphalyte (1 ml/kg BW, Pfizer, UK), and
complement the treatment from solely FCV per rectum to
i/v plasma and GCV. The calf first displayed clinical signs
of haemorrhagic disease six days into the DNAemia:
oedema of the head and ventral abdomen, tongue pe-
techiae and progressive signs of cyanosis. The platelet
count had also reduced drastically at this point to 98*109/
L and viral load had increased to 7.2*106 vgc/ml of blood.
Intravenous cannulas were in place in both ears for ad-
ministration of 1 ml/kg plasma TID, fluids and antibiotics
(2 mg/kg marbofloxacin, Marbocyl®, Vetoquinol). Due to
logistics, GCV (5 mg/ml) could not be administered until
16:00h that day, but achieved plasma levels of 2529 ng/ml
following i/v injection. Clinical signs progressed despite
treatment and the platelet count further reduced to
13*109/L and viral load increased to 1.9*107 vgc/ml of
blood. The calf subsequently died at midnight, just into
the next day as a result of hypoxaemia and hypovolaemia.
Discussion
The early clinical signs of EEHV-HD are non-
pathognomonic and often manifested as lethargy, anorexia
and lameness. As a consequence of generalized capillary
endothelial cell damage, these early clinical signs are likely
to be followed by more severe and generally terminal signs
[5, 8, 12]. Routine blood testing of at-risk Asian elephants
for EEHV viraemia has been suggested as part of a
Fig. 3 Penciclovir, the metabolite of famciclovir, plasma levels in 2 juvenile Asian elephants with EEHV-1A DNAemia. Famciclovir (FCV) was rectally
administered in Case 1 at 15 mg/kg twice daily (BID) on observation of clinical signs indicative of EEHV-1A infection (Day 0) and continued at the
same dose rate until Day 1, when it was reduced to 12 mg/kg thrice daily (TID). This was followed by further reduction on Day 3 to 8 mg/kg BID
and continued unchanged until Day 18. In Case 2 FCV was administered at 15 mg/kg TID for two days following the detection of EEHV-1A DNA
in the blood (Day -5), five days prior to observation of EEHV-1A clinical signs, and continued at the same dosage till the last dose of FCV at 9:00
am on Day 0; blood was only collected at 17:00 pm on that day. The death of Case 2 was at midnight on Day 1; seven days after first detection
of EEHV-1 DNA in the blood. Dashed line indicates the minimum level of PCV considered therapeutic in humans with genital herpes
(>100 ng/ml) [27]
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monitoring scheme to predict and potentially prevent fatal
disease, as the viral DNA can be detected at least several
days prior to any clinical signs [13, 14]. This routine
monitoring was proven to be valuable in this study, where
Case 2 continuous EEHV-1 DNAemia was detected five
days prior to the earliest clinical signs, although unfortu-
nately this early initiated treatment was not able to pre-
vent fatality.
In addition to detection and quantification of viral DNA
through real-time qPCR, drop in the monocyte/neutrophil
ratio, and absolute reduction of the platelet count, make
both the monocytes and platelets the most useful prognos-
tic haematological parameters of EEHV-HD, although the
exact physiological process for these changes is as yet un-
known. It is possible that the monocytes are subjected to
immediate assault of the virus [19], and that the viral dam-
age to the endothelial cells beyond the adaptive nature of
the host response leads to the development of dissemi-
nated intravascular coagulation (DIC) and hence critical
loss of platelets. In Case 2, the platelet count showed a
gradual decline well before the fatal progressive viraemia,
reaching a dangerously low level before death. Archived
data from three previous EEHV fatalities at the same col-
lection show a similar critically low platelet count following
clinical EEHV-1 manifestation (Table 2). Similar findings
have also been recently reported from Asian elephants
affected by EEHV-1B, 4 and 5 viraemia [13, 18, 19]. It is
noteworthy that mean haematological parameters vary
substantially in Asian elephants’ blood, e.g. a reported
range of 80-975*109/L for platelets [31–35]. Monocytes are
usually the most abundant white blood cells in the majority
of juveniles. In these cases, the relative drop of monocytes,
compared to neutrophils, in the early stages of the disease
could easily be identified on straightforward in-house white
blood cell differentials. There are, however, individuals in
which the monocytes are on average less abundant and
hence this early indicator will be less beneficial in these
cases. It is therefore advisable to establish individual base-
lines for at least the abovementioned haematological
parameters for each at-risk elephant in advance, and that
clinicians familiarise themselves with in-house blood smear
differentials.
Monitoring kinetics of EEHV-1A load in the two
elephants revealed rapid increase in viral load in the ele-
phant that succumbed to the disease (Case 2) despite con-
tinuous anti-herpesviral treatment up to the EEHV-1
clinical signs. From at least three days prior to onset of
clinical signs, PCV reached plasma levels suggested as
therapeutic for treatment of diseases caused by alphaher-
pesviruses infections in humans [27], but here it had failed
to control virus replication as the virus load continued to
increase. Considering the approximate three hour half-life
Table 2 Haematological parameters of three additional fatal cases of EEHV-1A and EEHV-1B infections from the same zoological
collection
Animals
(date of sampling)
Virus type WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
Emilia
(18/12/2006) EEHV-1B 17 11.85 3.21 1.9 (11.2 %) 0.03 0.02
Riddle
(01/05/2009) EEHV-1A 2.71 1.49 0.84 0.27 (10 %) 0 0
Betts
(15/05/2009) EEHV-1A 5.1 3.11 1.02 0.97 (19 %) 0 0
Physiological mean
(% of WBC)
15.51 3.77
(25.5 %)
5.02
(23.65 %)
6.46
(50 %)
0.24
(1.55 %)
0.02
(0.10 %)
Animals
(date of sampling)
RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH (pg) MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
Emilia
(18/12/2006) 3.05 12.8 39.2 122 42 34.4 15.7 34.6 NA
Riddle
(01/05/2009) 3.55 13 37.7 106 36.7 34.6 17.4 25.6 35
Betts
(15/05/2009) 3.16 12.9 55.1 112 40.8 36.5 17.3 71.5 NA
Physiological (mean) 3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
Blood samples were taken following the observation of EEHV-1 infection clinical signs. WBC, lymphocyte, monocyte and platelet counts (highlighted in bold)
consistently show substantial drop from their physiological level in the two fatalities caused by EEHV-1A. Percentages of monocytes in the white blood cells are
also given in the table
WBC, white blood cell count; RBC, red blood cell count; HGB, haemoglobin; MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHV, mean
corpuscular haemoglobin volume; RDW, red blood cell distribution width; PLT, platelet count; PCV, packed cell volume; NA, not available
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of PCV [27], the peak levels could have been up to three
times higher than measured, as blood samples were taken
6-8 hours following the FCV administration.
The efficacy of FCV treatment to curb progression to
EEHV-HD in clinical EEHV has always been debatable,
as compromised cellular function at enteric level could
affect absorption. This was indicated by the measured
PCV level in Case 2, which dropped remarkably 48
hours prior to the onset of outwardly visible clinical
signs. Factors such as drug expulsion and individual dif-
ferences in drug metabolism are also considered possible
causes of this drop [24]. These findings therefore favour
those anti-herpesviral drugs that could be administered
intravenously, to bypass the intestinal absorption step.
Additionally, the available sequences for EEHV TK and
PK have only 25 % amino acid identity with their ortho-
logues in HSV and HCMV, target viruses for these drugs
[9] and indirect surrogate in vitro assays have shown
mild sensitivity for only the PK against PCV [36].
Taking into account the EEHV viraemia sequel follow-
ing FCV administration in current and previous studies,
the efficacy of FCV remains doubtful. Therefore the use
of other, i/v administered and potentially more effective,
anti- herpesviral therapies should be explored, especially
in cases where pre-EEHV-HD viraemia, established
through routine blood PCR monitoring, does not appear
to be affected by FCV within the first days of treatment.
In the absence of comprehensive data on a highly effect-
ive and safe anti-herpesviral drug, alternative drugs at
present could include i/v administered nucleoside ana-
logues such as GCV and ACV. The second-line drugs
could be the pyrophosphate analogue foscarnet and the
nucleotide analogue cidofovir, but these drugs all have
their own safety issues. The most common adverse effect
during GCV therapy in humans has been haematological
toxicity, but this appears to be readily reversible on dis-
continuation of the drug [37]. It should also be noted
that ACV is a hundred times more potent than FCV in
inhibiting herpesviruses replication, but it suffers from a
shorter half-life and intracellular concentration [38].
This drug has been recommended for clinical situations
in humans where a rapid decrease in viral load is desir-
able, and could be of similar therapeutic value in EEHV
clinical infections. The renal toxicity of the drug should
also be considered in its therapy. Frequent measurement
of EEHV load in blood samples is therefore of para-
mount value to establish the efficacy of ongoing therapy.
Complementary therapies that are likely to be of value
include supportive therapies e.g. maintaining hydration
and actions to prevent DIC and shock, such as i/v
plasma administration from EEHV antibody positive
adult donors, as a source of both antibodies and plate-
lets, and a broad spectrum antibiotic to combat potential
concurrent bacterial infections that might possibly be at
the root of triggering the viral replication, predisposing
to the infection or arise as a secondary infection.
Intravenous access appears to be of significant value
for supportive treatment and anti-viral drug administra-
tion, and is straightforward in trained elephants that are
used to being handled. The EEHV Advisory Group
convened to debate this in 2014 and currently recom-
mends minimum standards of care for all at-risk elephants
irrespective of management systems, which include a
section on Calf Training for intravenous access (www.eeh
vinfo.org). In elephants that have not attained this stage of
training at the time of infection, repeated standing seda-
tions using butorphanol and detomidine are possible, as
used successfully in other institutions (Lauren Howard,
personal communication).
As far as antibodies are concerned, Case 1 had been
positive on an indirect ELISA for glycoprotein B (gB)
about 9 months prior to the clinical signs and survived
the viraemia [17]. On the other hand, Case 2 was also
highly positive on the same gB ELISA (van den Doel,
pers. communication) at the time of EEHV infection,
but succumbed to the virus. For other closely related
betaherpesvirus infections (e.g. HCMV), antibodies to
the gB protein seemed to enhance protection by curbing
at least the dissemination of the virus in the blood [29].
However, considering the fatality in Case 2 despite high
anti-gB antibody, sole measurement of gB antibody may
not be an indicator of protection against EEHV, as it is
currently unknown which viral proteins are targeted by
neutralising antibodies. The possibility also exists that
early IgG antibodies to EEHV show a low avidity for the
antigen and hence an avidity test is required to deter-
mine the value of antibodies against EEHV [39]. Also, in
the view that herpesviruses (EEHVs and elephant gamma
herpesviruses [EGHVs]) are ubiquitous in Asian elephant
populations, the notion that the above mentioned ELISA
is cross reactive with gB of similar viruses or other un-
known agents cannot be excluded [9].
In this study, a detectable EEHV-1 DNAemia was corre-
lated with the disease symptoms only when the blood viral
load was at around 8.16*103 vgc/ml of blood for Case 1 and
7.2*106 vgc/ml for Case 2. A previous report states that a
threshold of around 1.0*104 vgc/ml of blood had coincided
with apparent illness [14]. Clinical signs appeared at a much
higher viral load in Case 2, emphasising a daily rapid increase
in viral load as a more favourable determinant of initiating
anti-herpesviral therapy, its success and disease prognosis.
Our results also further endorse that DNAemia precedes
virus shedding in trunk secretions of EEHV-1A infected
animals, similar to those reported previously [13, 14, 18, 19].
Although there is no evidence that infectious particles are
shed at a level sufficient to infect an in-contact animal, the
potential risk these carrier elephants may pose following a
clinical EEHV case should be considered.
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Conclusions
The EEHV viraemic cases investigated here further high-
light the ongoing threat posed by the virus to the juvenile
Asian elephants, potentially leading to gradual disappear-
ance of their free-living population and an inability to
maintain a viable captive population to safeguard the spe-
cies from extinction. Therefore, effective control of future
EEHV infections is fundamental to improve the survival
rate of affected animals. Routine EEHV testing combined
with viral quantification, WBC, monocyte and platelet
counts following confirmed DNAemia in at-risk elephants
should deliver an early warning of the clinical disease and
prognosis, providing enough time to evaluate treatment
opportunities to avert a fatal outcome. This investigation
further questions the efficacy of the rectally administered
FCV in controlling the viraemia and urges towards the ex-
ploration of alternative therapies. These therapies could in-
clude preferably i/v administered anti-herpes viral drugs,
complementary plasma transfusions and antibiotics against
potential secondary infections.
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